Bulk Pharmaceutical API Sources for IOBENGUANE I-131

Bulk Pharmaceutical API Sources for IOBENGUANE I-131

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		71184
ABI Chem		AC1L2FP4
ABI Chem		AC1Q50E4
ChemMol		99146549
Chemieliva Pharmaceutical Co., Ltd		PBCM0829560
THE BioTek		bt-271519
BLD Pharm		BD01387809

Bulk Active Pharmaceutical Ingredient (API) Sources for: Iobenguane I-131

Last updated: July 30, 2025

Introduction

Iobenguane I-131, also known as Metaiodobenzylguanidine labeled with iodine-131, is a targeted radiopharmaceutical used predominantly in the diagnosis and treatment of neuroendocrine tumors such as pheochromocytoma and paraganglioma. Given its specialized application, secure and consistent sourcing of high-quality bulk API is fundamental for pharmaceutical manufacturers, healthcare providers, and investors. This article explores the global landscape of API suppliers for iobenguane I-131, including market dynamics, regulatory considerations, and key players.

Market Overview and Significance

The demand for iobenguane I-131 arises primarily from niche oncology markets. Despite its limited market size, its clinical significance drives a specialized supply chain. The radiopharmaceutical's production hinges on complex manufacturing processes involving the synthesis of precursor compounds, radioisotope labeling, and stringent quality controls, necessitating suppliers with advanced capabilities, strict compliance, and reliable delivery.

Primary Suppliers of Iobenguane I-131 API

The supply chain for iobenguane I-131 API is characterized by a select group of suppliers with established expertise in radiopharmaceutical synthesis and isotopic manufacturing. These organizations operate within a regulated framework (FDA, EMA, and other health authorities) and often collaborate directly with pharmaceutical developers or through license agreements.

1. Nordion (Canadian Nuclear Laboratories)

A pivotal player historically involved in radionuclide production, Nordion provides isotopes and key radiopharmaceuticals. Its isotope production facilities can supply high-purity iodine-131, an essential component in synthesizing iobenguane I-131. While Nordion focuses broadly on medical isotopes, its capacity to produce the requisite radioisotope positions it as a strategic API source, primarily through licensing and partnerships with radiopharmaceutical manufacturers.

2. Curium Pharma (a subsidiary of IBA Group)

Curium Pharma specializes in pharmaceutical isotopes, including iodine-131, and has production facilities aligned with Good Manufacturing Practice (GMP) standards. Their ISOTOPES division offers high-grade iodine-131, often used in diagnostic and therapeutic applications. Collaborations with pharmaceutical companies facilitate the conversion of isotope supplies into active API suitable for clinical use.

3. Hokan Corporation

Based in Japan, Hokan Corporation produces radioisotopes, including iodine-131. Their manufacturing process emphasizes high radionuclidic purity and compliance with international standards. While primarily serving regional markets, their expertise and capacity make them a notable provider for API conversion.

4. ARTEMIS Tomsk

A Russian state-backed enterprise involved in nuclear medicine isotope production, ARTEMIS Tomsk supplies iodine-131 and related radiochemicals. Their capacity for large-scale isotope production, combined with research collaborations, positions them as a significant API source for qualified partners.

5. NTP Radioisotopes (South Africa)

NTP Radioisotopes has established distribution channels for iodine-131. While primarily offering radioisotopes, their production pipeline supports the supply of raw materials needed for API synthesis in radiopharmaceutical manufacturing, contingent upon access to specialized synthesis facilities.

---

Manufacturing and Supply Chain Considerations

• Complex Synthesis and Handling: The production of iobenguane I-131 API involves labeling of the benzylguanidine compound with iodine-131, which itself is produced via cyclotron irradiation of enriched tellurium targets. Suppliers must ensure radionuclidic purity and stable chemical conjugation, demanding sophisticated infrastructure.

• Regulatory Compliance: Suppliers are required to comply with international Good Manufacturing Practices (GMP). This compliance ensures quality, safety, and efficacy of the API, especially given the radiological nature of the compound.

• Supply Security: The limited number of isotope production facilities, especially those capable of supplying high-purity iodine-131, constrains supply chain robustness. Market players often rely on strategic partnerships and long-term supply agreements.

• Geopolitical Factors: Political stability and nuclear safety policies influence regional isotope production, impacting global API supply. Centralized production facilities in Canada, Russia, and South Africa are critical nodes, and geopolitical developments can disrupt supplies.

Regulatory Landscape

Obtaining regulatory approval for API suppliers is critical. Manufacturers typically require endorsements or certifications such as EMA GMP certificates or FDA approval. Suppliers should demonstrate consistent quality control, radionuclidic purity, and documentation to meet these standards.

Future Outlook and Trends

The production of high-quality iodine-131 is expected to expand following increased clinical interest in targeted radiotherapy (e.g., for neuroendocrine tumors). Emerging manufacturing technologies, including reactor-based and cyclotron-based isotopic production, aim to increase yield and reduce reliance on limited facilities. Collaborations between nuclear reactor operators and pharmaceutical producers are likely to enhance API availability.

Additionally, advancements in automation and radiochemical synthesis may streamline production, reduce costs, and improve supply reliability. Governments and industry consortia increasingly prioritize securing isotopic supply chains to meet growing clinical demands.

---

Key Challenges

• Limited number of high-capacity isotope production facilities.
• Nuclear regulatory constraints delaying new capacity deployment.
• Complex synthesis processes requiring specialized expertise.
• Susceptibility to geopolitical and supply chain disruptions.

Strategic Recommendations

• Establish long-term agreements with multiple API suppliers to mitigate supply risks.
• Monitor regulatory changes and accreditation status of suppliers.
• Invest in alternative production technologies and regional diversification.
• Collaborate with suppliers capable of meeting GMP standards and demonstrating consistent radionuclidic purity.

---

Key Takeaways

• The supply of iobenguane I-131 API relies on a select group of specialized isotope producers, predominantly located in North America, Europe, and Asia.
• High standards for radionuclidic purity, quality control, and regulatory compliance are central to sourcing high-quality API.
• Supply chain vulnerabilities stem from limited production capacity, geopolitical factors, and regulatory delays.
• Strategic partnerships, diversification, and technological innovation are essential for securing reliable API supply.
• Industry stakeholders should closely monitor developments in isotope production infrastructure and regulations to optimize procurement strategies.

---

FAQs

1. What are the main challenges in sourcing API for iobenguane I-131?
The primary challenges include limited production capacity of high-purity iodine-131, complex synthesis requiring specialized expertise, strict regulatory compliance requirements, and geopolitical factors influencing isotope availability.

2. Which countries are leading producers of iodine-131 API?
Leading producers include Canada (Nordion), Japan (Hokan Corporation), Russia (ARTEMIS Tomsk), and South Africa (NTP Radioisotopes). These regions host major isotope manufacturing facilities capable of supplying high-quality iodine-131.

3. How does regulatory approval impact API sourcing?
Regulatory approval guarantees that API suppliers meet international quality standards such as GMP, radionuclidic purity, and safety protocols, critical for pharmaceutical manufacturing and patient safety.

4. Are there any emerging technologies that could improve API supply?
Yes, innovations in cyclotron and reactor-based isotopic production, automation of synthesis processes, and regional isotope facilities aim to increase yield, reduce costs, and diversify supply sources.

5. What strategic steps should pharmaceutical companies take in API procurement?
Companies should establish multi-source supply agreements, track suppliers’ regulatory compliance, invest in alternative production methods, and develop contingency plans to manage supply disruptions.

---

References

[1] International Atomic Energy Agency (IAEA). "Production of Radionuclides," IAEA Report, 2020.
[2] Nordion. "Medical Isotopes Portfolio," Nordion Product Literature, 2022.
[3] Curium Pharma. "High Purity Iodine-131 Supply," Curium Official Website, 2023.
[4] ARTEMIS Tomsk. "Radiopharmaceutical Production Capabilities," Official Release, 2021.
[5] NTP Radioisotopes. "Global Isotope Supply Chain," NTP Annual Report, 2022.